MATINAS BIOPHARMA HOLDINGS, INC. Amortization of Debt Discount (Premium)
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Amortization of Debt Discount (Premium) of -$17.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2024-12-31 was -$1.00K, a 105.88% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2024-09-30 was $3.00K, a 82.35% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2024-06-30 was -$37.00K, a 227.59% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2024-03-31 was $18.00K, a 59.09% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. amortization of debt discount (premium) for fiscal 2024 was -$17.00K, a 115.89% decline from fiscal 2023.
- MATINAS BIOPHARMA HOLDINGS, INC. amortization of debt discount (premium) for fiscal 2023 was $107.00K, a 49.29% decline from fiscal 2022.
- MATINAS BIOPHARMA HOLDINGS, INC. amortization of debt discount (premium) for fiscal 2022 was $211.00K, a 15.60% decline from fiscal 2021.
- MATINAS BIOPHARMA HOLDINGS, INC. amortization of debt discount (premium) for fiscal 2021 was $250.00K, a 4.24% increase from fiscal 2020.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 3 month as first filed | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 6 month as first filed | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 9 month as first filed | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.00K derived: sum of 2 quarters · filed 2026-03-31 | -$35.00K derived: sum of 3 quarters · filed 2026-03-31 | -$17.00K 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$34.00K derived: sum of 2 quarters · filed 2025-11-10 | -$16.00K 10-Q · filed 2025-11-10 | $1.00K derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | -$37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$19.00K 10-Q · filed 2025-08-14 | -$2.00K derived: sum of 3 quarters · filed 2025-08-14 | $15.00K derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $18.00K 10-Q · filed 2025-05-15 | $35.00K derived: sum of 2 quarters · filed 2025-05-15 | $52.00K derived: sum of 3 quarters · filed 2025-05-15 | $81.00K derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $34.00K derived: sum of 2 quarters · filed 2025-04-15 | $63.00K derived: sum of 3 quarters · filed 2025-04-15 | $107.00K 10-K · filed 2025-04-15 | ||||
| 2023-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $46.00K derived: sum of 2 quarters · filed 2024-11-13 | $90.00K 10-Q · filed 2024-11-13 | $143.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $73.00K 10-Q · filed 2024-08-14 | $126.00K derived: sum of 3 quarters · filed 2024-08-14 | $174.00K derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $44.00K 10-Q · filed 2024-05-09 | $97.00K derived: sum of 2 quarters · filed 2024-05-09 | $145.00K derived: sum of 3 quarters · filed 2024-05-09 | $194.00K derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $101.00K derived: sum of 2 quarters · filed 2024-03-27 | $150.00K derived: sum of 3 quarters · filed 2024-03-27 | $211.00K 10-K · filed 2024-03-27 | ||||
| 2022-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $97.00K derived: sum of 2 quarters · filed 2023-11-08 | $158.00K 10-Q · filed 2023-11-08 | $157.55K 10-Q · filed 2022-11-02 | $235.77K derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $110.00K 10-Q · filed 2023-08-09 | $109.57K 10-Q · filed 2022-08-11 | $187.77K derived: sum of 3 quarters · filed 2023-08-09 | $251.44K derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $61.00K 10-Q · filed 2023-05-10 | $60.89K 10-Q · filed 2022-05-12 | $138.77K derived: sum of 2 quarters · filed 2023-05-10 | $202.44K derived: sum of 3 quarters · filed 2023-05-10 | $256.75K derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $77.77K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $141.44K derived: sum of 2 quarters · filed 2023-03-15 | $195.75K derived: sum of 3 quarters · filed 2023-03-15 | $250.00K 10-K · filed 2023-03-15 | $250.45K 10-K · filed 2022-03-08 | |||
| 2021-09-30 | $63.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $117.98K derived: sum of 2 quarters · filed 2022-11-02 | $172.23K 10-Q · filed 2022-11-02 | |||||
| 2021-06-30 | $54.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $108.56K 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | $54.25K 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | $239.83K 10-K/A · filed 2022-03-11 | |||||||
| 2019-12-31 | $140.00 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |